AegirBio AB announced the initiation of a development and licensing agreement with iSTOC. The agreement covers the development of a data management platform for the recently CE-marked Magnia® Reader based natalizumab Point of Care (POC) therapeutic drug monitoring (TDM) test. The deliverables will include a web-based information dashboard and a mobile app to upload data readouts from the Magnia Reader.

This platform will provide an interface between electronic medical records and be a foundation for easy integration of the company's assays into clinical, POC, and at-home workflows, both for upcoming trials and everyday patient care.